Floatz logo

Risperdal

Schizophrenia, Schizoaffective Disorder

Hoffmann-La RochePhase 4 / ApprovedDormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Schizophrenia, Schizoaffective Disorder cohort.

Asset / SponsorPhaseRating
ZIPRASIDONE
Central Institute of Mental Health, Mannheim
Phase 4BB
Ralmitaront
Hoffmann-La Roche
Phase 2B
Olanzapine
Teva Branded Pharmaceutical Products R&D LLC
Phase 1CC
Topamax
Centre for Addiction and Mental Health
N/AD

Same molecule, other indications

Risperdal is also rated in:

major depressive disorderDormant
BBB
Indicative ·
78 / 100
View asset →
psychotic disorderDormant
BBB
Indicative ·
77 / 100
View asset →
schizoaffective disorderDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →